The results of using effective hormone concentrations in B. monnieri plant cultures demonstrated that when concentrations of 2 μg/mL or higher of the specified extracts were applied to the culture medium of normal and cancerous skin cells, there was a significant increase in the number of cancerous cells and a concurrent decrease in normal cells.
No tolerable upper Dietary Reference Intake (DRI) has been established for flavonoids, and consuming them in typical food amounts poses no toxicity risk. However, excessive intake through high-potency supplements may lead to flavonoid toxicity. Vulnerable populations, such as the elderly with marginal iron deficiency, may face risks since flavonoids can bind nonheme iron (
18). While most flavonoids are generally safe, excessive consumption has been associated with adverse effects, including gastrointestinal symptoms, hemolytic anemia, hepatotoxicity, and potential interactions with medications (
19). Long-term use of flavonoids has also been linked to conditions such as contact dermatitis in sensitive individuals and estrogen-related effects in men and breast cancer (
20).
The results indicated that none of the studied treatments caused a significant reduction in cancer cells compared to the control. Based on this finding, the use of
B. monnieri under the applied treatments is not recommended for controlling the growth of skin cancer cells. However,
B. monnieri has shown promising results in studies involving other cancer cell types. The anticancer effects of
B. monnieri remain unproven at the clinical level in humans. Currently, no clinical evidence supports the potential anticancer activity of this plant. Reports indicate that the methanolic extract of
B. monnieri contains phenolic bioactive molecules that act by inhibiting cell motility (
4). Studies on certain cancer cell lines have revealed that
B. monnieri initiates DNA fragmentation after treatment. The proposed mechanism of action involves bacoside A binding to the enzyme CaMK2A. This binding triggers phosphorylation, enabling CaMK2A to interact with ryanodine receptors on the endoplasmic reticulum membrane. This interaction increases calcium ion release, leading to significant fluid absorption via macropinocytosis.
Consequently, cells swell and eventually undergo lysis (
4). Research indicates that the ethanolic extract of
B. monnieri regulates endogenous oxidative marker levels in the brains of pre-pubescent mice (
21). A study by Russo et al. investigated DNA damage and cytotoxicity caused by H₂O₂ in human non-immortalized fibroblast cells treated with ethanolic
B. monnieri extract. Their findings revealed that the extract inhibits superoxide anion formation, demonstrating its free radical scavenging ability. It provides protective effects against H₂O₂-induced cytotoxicity and DNA damage (
22).
Histological and animal studies have shown that
B. monnieri extract enhances the system's defense against oxidative stress by reducing free radical formation in the brain (
21). Bacosides in
B. monnieri inhibit lipoxygenase activity, eliminate free radicals, and protect neurons in the prefrontal cortex, hippocampus, and striatum from cytotoxicity and DNA damage associated with Alzheimer's disease. Additionally, bacosides increase glutathione peroxidase activity, facilitate iron chelation, and promote nitric oxide-mediated cerebral vasodilation, resulting in improved memory performance (
23).
It is believed that bacosides repair damaged neurons by enhancing kinase activity and neurosynthesis, restoring synaptic activity and improving nerve impulse transmission (
24). Studies have demonstrated that oral administration of
B. monnieri extract increases antioxidant levels such as SOD, GSH, and CAT, while reducing free radicals like LPO and NO. It also accelerates wound closure in mice due to its antioxidant properties (
25). Furthermore,
B. monnieri ethanol extract at 20 mg/kg body weight inhibits tumor progression by reducing LDH levels (
26).
The extract of
B. monnieri enhances autophagy, indicating a novel function that warrants further investigation (
4).
The results showed that a concentration of 0.5 μg/mL 2IP significantly increased the survival of normal cells while having no notable effect on the survival of cancer cells. PGRs play a critical role in the accumulation of bioactive compounds. The type and concentration of auxins and cytokinins influence growth and product formation in callus and plant cell suspension cultures, with hormone concentration being a key factor in the accumulation of secondary metabolites such as phenolics and flavonoids (
7). For example, research on
Garcinia brasiliensis Mart. callus cultures demonstrated that treatment with 2,4-D and 2IP significantly increased total flavonoid levels (
27). Similarly, studies on date palm suspension cultures found that a combination of 1 mg/L 2,4-D and 5 mg/L 2IP enhanced biomass accumulation, while treatment with 5 mg/L 2,4-D and 2.5 mg/L 2IP induced notably higher levels of phenolics and flavonoids (
28). These findings highlight the importance of optimizing hormone concentrations to achieve balanced enhancement of both biomass and secondary metabolite production.
In the context of flavonoids, apigenin—a subtype of flavones—has demonstrated efficacy against various cancer types, including prostate cancer, colon cancer, breast cancer, and melanoma. Apigenin has been shown to inhibit metastasis, cell migration, invasion, and epithelial-mesenchymal transition (EMT) across these cancer models. Notably, it has been observed to reduce stem cell properties in breast cancer cells (
29). This underscores the potential of flavonoid compounds in cancer treatment, further emphasizing the importance of PGR-optimized secondary metabolite production for therapeutic applications.
5.1. Conclusions
This study developed an efficient, effective, and reproducible protocol for the micropropagation of B. monnieri, which is at risk of extinction from its natural habitat. Additionally, the extract obtained from B. monnieri contained a high amount of secondary metabolites. This is the first report in which active compounds derived from tissue culture of B. monnieri were tested on different cell types. The use of hormones to increase flavonoid content in B. monnieri demonstrated that these hormones can significantly enhance flavonoid levels. However, the application of this plant under the mentioned treatments is not recommended for the treatment of skin cancer, and further research is necessary.
Regarding the effect of the studied treatments on normal cells, the results showed that a concentration of 0.5 μg/mL 2IP significantly increased the growth of fibroblast cells. Based on this finding, the use of this hormone in the tissue culture of the B. monnieri plant is recommended to enhance the viability of fibroblast cells for use in cosmetics and health products, although additional studies are required.